JPI Healthcare Reports Q1 2026 Operating Profit of KRW 4.6B and Declares KRW 1.28B Cash Dividend

Q1 2026 consolidated revenue KRW 10.8B, operating profit KRW 0.46B, net profit attributable to parent KRW 1.74B
Core product X-ray grid sales KRW 6.3B (58.9% of total); overseas sales over 85%
Expanding sales of next-gen medical imaging devices (StriXion, DeteCT, etc.)
First quarterly report since KOSDAQ listing in Aug 2025; stable financial structure (debt ratio 30.7%, net debt ratio 17.2%)
Declared cash dividend of KRW 1.28B (approx. KRW 250 per share) resolved by board in Feb 2026
R&D expenses KRW 0.84B (8.5% of revenue); holds 97 IP rights domestically and internationally
Maintains stable supply relationships with major global customers (GE, Siemens, Philips, etc.)
Granted 60,000 stock options (exercise price KRW 13,500); recognized compensation cost of KRW 0.74B in current quarter
Subsidiary JPI Healthcare Solutions continues quarterly net loss of KRW 0.43B and is in capital impairment
Credit rating maintained at A- (NICE, Feb 2026)